secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2026-11-09T13:04:59+00:00
Accession:  0001193125-26-452706
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Mentari Therapeutics closes InMed merger, raises $490M; MTRI begins Nasdaq trading Nov 9
--------------------------------------------------------------------------------

- Merger with InMed Pharmaceuticals completed; combined company is Mentari Therapeutics, trading on the Nasdaq Capital Market under ticker MTRI from Nov 9, 2026.
- Private financings totaled ~$490M gross, led by Fairmount, with Venrock, Blackstone, RTW, Wellington, a16z Bio + Health and others; includes conversion of $50.0M of convertible notes.
- ~58.3M shares and common stock equivalents outstanding after reverse split, financings and merger (excluding equity awards); proceeds fund runway into 2029 and beyond.
- MT-001 anti-PACAP monoclonal antibody in Phase 1 with initial data expected mid-2027; MT-002 PACAP/CGRP bispecific on track for regulatory filing Q1 2027, data by year-end 2027.
- Greg Divis is CEO of the combined company; Todd Shegog appointed to the board as Audit Committee chair in connection with the closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000119312526452706/0001193125-26-452706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000119312526452706/d183007d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-452706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer